Scientists move towards stem cell therapy trials to mend shattered bones

The UK Stem Cell Foundation, the Medical Research Council and Scottish Enterprise, in partnership with the Chief Scientist’s Office, are funding a £1.4 million project to further the research at the University of Edinburgh with a view to setting up a clinical trial within two years.

The initiative could have a major impact on treating conditions such as osteoarthritis as well as treating trauma victims whose bones have been shattered beyond repair.

It involves using a “bioactive scaffold” made to protect the stem cells and simulate their growth into bone or cartilage once they are placed in the affected area. The scaffold consists of a fairly rigid mesh structure, coated or impregnated with a drug that affects the patients cells.

Dr Brendon Noble, of the University of Edinburgh’s MRC Centre for Regenerative Medicine, said: “This is a novel approach in terms of treating damaged bones and cartilage. The aim is to translate the knowledge we have gained from bone biology studies into tangible treatments for patients.”

Researchers will also work with clinicians, headed by Hamish Simpson, professor of orthopaedics and trauma at the University of Edinburgh, with a view to eventually translating their findings into treatments for patients.

As well as using cells derived from bone marrow, the scientists will work in collaboration with the Scottish National Blood Transfusion Service to culture bone forming cells derived from blood.

The advantage of these blood-sourced cells is that they can be extracted without the need for surgery. The use of a patient’s own stem cells means that they are also unlikely to be rejected.

Dr Anna Krassowska, research manager for the UK Stem Cell Foundation said: “In the UK hip fractures kill 14,000 elderly people every year - more than many cancers. The worldwide market for orthopaedic devices alone represents some $17 billion. This research has the potential not only to impact on a significant number of people's lives but to open up one of the largest stem cell markets in the industry.”

For nearly a decade, scientists have known broadly the right chemical conditions required to encourage undifferentiated stem cells taken from a patient's bone marrow to change into bone and cartilage cells in the laboratory. However, the use of the “bioactive scaffold” being developed at the University of Edinburgh aims to enable these cells to grow within the human body. The initial clinical trial, resulting from the laboratory work is likely to involve around 30 patients.

Source: University of Edinburgh

Related stories:

Scientists prove endothelial cells give rise to blood stem cells
Stem cell researchers at UCLA have proven definitively that blood stem cells are made during mid-gestational embryonic development by endothelial cells, the cells that line the inside of blood vessels.
New 'control knobs' for stem cells identified
Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.
Stem cell obstacles
"There are still a number of major hurdles in the path of stem cell research today that are preventing the routine application of the technology in regenerative medicine." So say UK scientists writing in a forthcoming issue of the International Journal of Biotechnology.
Superglue from the sea: Synthetic sea worm glue may mend shattered knee, face bones
Sandcastle worms live in intertidal surf, building sturdy tube-shaped homes from bits of sand and shell and their own natural glue. University of Utah bioengineers have made a synthetic version of this seaworthy superglue, and hope it will be used within several years to repair shattered bones in knees, other joints and the face.
Sweet success for new stem cell ID trick
(PhysOrg.com) -- Biomaterial scientists in Manchester believe they have found a new way of isolating the ‘ingredients’ needed for potential stem cell treatments for nerve damage and heart disease.
Adult stem cell breakthrough
(PhysOrg.com) -- The first tissue-engineered trachea (windpipe), utilising the patient's own stem cells, has been successfully transplanted into a young woman with a failing airway. The bioengineered trachea immediately provided the patient with a normally functioning airway, thereby saving her life.
Researchers to use patient's own stem cells to treat heart failure
Researchers at the University of Utah are enrolling people in a new clinical trial that uses a patient's own stem cells to treat ischemic and non-ischemic heart failure.
Intraspinal implant of mesenchymal stem cells may not heal the demyelinated spinal cord
Multiple sclerosis is a disease caused by the loss of the myelinated sheath surrounding the nerve fibers of the spinal cord. Therapeutic hope for curing multiple sclerosis and other demyelinating diseases has included the possibility that stem cell transplants could help remyelinate the spinal cord. Accordingly, researchers from the University of Cambridge (UK) conducted experiments using animal models to see if the direct implantation of multipotent mesenchymal stem cells (MSCs) (derived from a different rat's adult bone marrow, i.e. allogenic) into the demyelinated rat spinal cord would be therapeutic and remyelinate the damaged area.

News discussion:

General Science news